News

Zacks Investment Research on MSN6h
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular ...
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...
Novo Nordisk's CagriSema Shows Major Weight Loss In Late-Stage Trial
Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...
Jurnal Time6d
Discover Top 6 Ozempic Alternatives for Weight Loss!
Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication ...